Stephen Liu, MD, Georgetown University School of Medicine

Articles by Stephen Liu, MD, Georgetown University School of Medicine

The Future of Lung Cancer Treatment

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Mesothelioma: A Look at DREAM3R and PrECOG Trial

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Fundamentals of Mesothelioma

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Trials in Limited-Stage Small-Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Treatment for Progressive Small-Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Treatment Options in Small–Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Recent Advances in Small-Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Treatment for PD-L1 High/Low/Negative Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Understanding Immune Response in Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Chemotherapy and Immunotherapy in Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Treatment Options in PD-L1 Positive Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Treatment Efficacy in Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Frontline Treatment in Non–Small Cell Lung Cancer

BySuresh S. Ramalingam, MD, Winship Cancer Institute,Firas Badin, MD, Baptist Health,Christine Bestvina, MD, University of Chicago,Martin Dietrich, MD, PhD,Stephen Liu, MD, Georgetown University School of Medicine

October 26th 2020

Latest Updated Articles

Trials in Limited-Stage Small-Cell Lung Cancer
October 26th 2020
Fundamentals of Mesothelioma
October 26th 2020
Recent Advances in Small-Cell Lung Cancer
October 26th 2020
Understanding Immune Response in Non–Small Cell Lung Cancer
October 26th 2020
Treatment for PD-L1 High/Low/Negative Non–Small Cell Lung Cancer
October 26th 2020
Treatment Options in PD-L1 Positive Non–Small Cell Lung Cancer
October 26th 2020

Trending on OncLive

CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care

Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications

FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS

Integrating Bispecific Antibodies Into Frontline Therapy for Newly Diagnosed Multiple Myeloma

NAPISTAR-1-01 Data Support Rapid TUB-040 Development in Biomarker-Unrestricted Ovarian Cancer